Manufacturing of Solid Dosage Forms - 2011 - GBI Research Reports

Manufacturing of Solid Dosage Forms - 2011

Manufacturing of Solid Dosage Forms - 2011 - GBI Research Reports
Manufacturing of Solid Dosage Forms - 2011
Published Feb 10, 2011
81 pages — Published Feb 10, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research's report, Manufacturing of Solid Dosage Forms - 2011' Production Capacity May Force Regulatory Bodies to Re-Design Guidelines on Quality Standards. The report provides the key market data on the Contract Manufacturing Organization (CMO) market size for solid dosage forms along with forecast from 2009-2016 for API and excipient market. The report also gives insight into challenges, unmet needs, and technology landscape and cGMP guidelines for manufacturing of solid dosage forms. The report also analyzes the strengths, weaknesses, opportunities, and threats leading players involved in manufacturing of solid dosage forms. The report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts to provide a comprehensive view of the manufacturing of solid dosage forms.

The proper design and formulation of a solid dosage form requires knowledge about the physical, chemical and biological distinctiveness of pharmaceutical ingredients (API and excipients) to be used in manufacturing process. GBI research estimates that the APIs market was will grow from $62.5 billion in 2009 to an estimated at a CAGR of 5.8% between 2009 and 2016 to reach $91.3 billion by 2016. Growth in generics and oncology market and rising focus on high potency API are driving the growth of API market. The excipient market will also show a growth rate4% between 2006-2016 to reach $536m by 2016.the trend of outsourcing of the manufacturing operation to the CMO has increased in recent years and GBI Research estimates that CMO market manufacturing of for solid dosage forms will grow at a rate of growth from $11.2 billion in 2009 to reach $24.5 billion by 2016 with a CAGR of11.8% between 20092016.

Scope

The scope of this report includes -
- Key emerging technologies in the manufacturing of solid dosage forms
- Market revenues and forecasts for APIs, excipeints and CMO market for manufacturing of solid dosage forms.
- Qualitative analysis of the market drivers, barriers, future outlook and challenges for the API, excipient and CMO market.
- Manufacturing trends and new technologies used for manufacturing of solid dosage forms.
- Challenges and unmet needs in manufacturing of solid dosage forms.
- Regulatory aspects related to the manufacturing of solid dosage form.
- Single use technology trends, benefits, and challenges in downstream bioprocess that shape the bio manufacturing industry
- Analysis and competitive assessment of leading and evolving players involved in manufacturing of solid dosage forms.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Formulate strategies to increase your companys growth by understanding the new growth opportunities, market size and growth prospectus in market for manufacturing of solid dosage forms.
- Work around the technology hurdles by identifying the key trends shaping and driving the market for manufacturing of solid dosage forms.
- Device a more tailored country strategy through the understanding of key drivers and barriers to market for manufacturing of solid dosage forms.
- Differentiate yourself from competitors and develop new solutions for the manufacturing industry by understanding the existing competitive landscape and how it is evolving to meet the increasing demands.

  
Source:
Document ID
GBIHC079MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents45
  List of Tables71
  List of Figures81
Manufacturing of Solid Dosage Forms: Introduction91
  GBI Research Report Guidance91
Manufacturing of Solid Dosage Forms: Overview104
  General Manufacturing Process for Solid Dosage Forms101
    Dispensing101
    Sizing101
    Powder Blending111
    Granulation111
    Drying111
    Tablet Compression111
    Packaging111
  Granulation121
    Dry Granulation121
      Introduction121
      Advantages121
      Disadvantages121
    Wet Granulation121
      Introduction121
      Limitations of Wet Granulation131
Manufacturing of Solid Dosage Forms: Market Overview1421
  Overview of Drug Formulations Market141
  Solid Dosage Form Market152
  Drivers and Restraints in the Solid Dosage Market171
    Drivers171
      Pharmaceutical Sales Continue to Grow171
      Life Cycle Management Has Grown In Importance171
      Combination Drugs171
      Rise and Acceptance of Generics to Reduce Healthcare Costs171
      Global Expansion Strategies181
    Restraints181
      Maximum Biologics are in Liquid Dosage Forms181
      Inadequate Technical Expertise181
      Unstructured Industry181
      Unstructured Regulatory Framework181
  Major Components of the Solid Dosage Forms Market191
    Active Pharmaceutical Ingredients (APIs)191
    API Drivers201
      Growth in the Generic Sector is Fuelling Growth in Demand for APIs201
      Increasing Focus on Biological Drugs Contributes to the Growth of API Demand201
      The Rising Incidence of Lifestyle and Old Age Diseases is Boosting API Demand201
      Growth in Oncology is One of the Major Contributing Factors Behind the Growth of APIs201
      Increasing Focus on High Potency APIs Helps Market Growth211
    API Market Constraints211
      Maturity of the Market in Developed Regions Restricts Global API Revenue Growth211
      High Cost of New Drug Development Becomes a Hurdle to Innovation211
      Highly Fragmented Nature of Market Leads to Intense Competition and Price Reductions221
      Regulatory Challenges Delay the Launch of Drugs221
    Excipients233
    Excipients Drivers261
      Regulatory Developments261
      Decline of the Blockbusters271
      Cost Management271
      Counterfeits271
      Using Excipients with Multiple Functionalities281
    Excipients Restraints281
      No Defined Approval Process281
      No Quality Standardization281
      Highly Fragmented Market281
  Outsourcing of Manufacturing291
    Global Pharmaceuticals CMO Market Overview292
    CMO Market Size for Solid Dosage Forms311
    Key Drivers321
      Cost Advantages in Terms of Low-cost Labor, Cheaper Raw Materials and Cheaper Export Options321
      Flexibility in Terms of Production Volume321
      Risk Mitigation against Usage of Obsolete Technology and Variable Economic Conditions331
      Increased Efficiency Due to Increased Working Capital331
      Increased Focus on Core Competencies331
      Faster Time to Market, Thereby Boosting the Profitability and Lifecycle of a Drug331
    Key Restraints341
      Evolving Cases of Accountability341
      Highly Fragmented Market341
      Adoption of Evolving Technologies Needs to Pick Up Pace341
Manufacturing of Solid Dosage Forms: Technology Lanscape355
  Manufacturing Trends Used for Solid Dosage Forms351
  Innovative Technologies for Solid Dosage Manufacturing361
    Fluidized Hot-Melt Granulation361
    Hot-Melt Extrusion (HME)371
    Dry Emulsions371
    Bohle Tablet Coater (BTC)371
  Batch versus Continuous Process382
Manufacturing of Solid Dosage Forms: Challenges and Unmet Needs402
  Unmet Needs401
    Solid Dosage Products Based on High Active Compounds401
    Compliance with cGMP Guidelines401
    Redesigning Manufacturing Platforms401
  Challenges411
    Regulatory Hurdles for Continuous Process Facilities411
    Innovative and Efficient Excipients Required411
Manufacturing of Solid Dosage Forms: Regulatory Landscape4210
  cGMP Guidelines421
  For API cGMP Guidelines434
  Excipient Regulation471
    Comparison of the US, Europe and Japan471
  For Excipients cGMP Guidelines481
    The IPEC Excipient Guide481
    The IQA/PQG Guide481
    Application of the PQG standard491
    IPEC and PQG Standards Comparison501
    Regulatory Basis for Supplier Qualification511
Manufacturing of Solid Dosage Forms: Competitive Landscape5221
  Patheon521
    Company Overview521
    SWOT Analysis522
    M&A, and Licensing Deals541
  AAI Pharma551
    Company Overview551
    SWOT Analysis552
    M&A, and Licensing Deals571
  Famar581
    Company Overview581
    SWOT Analysis581
    M&A, and Licensing Deals591
  EGIS Pharmaceuticals PLC591
    Company Overview591
    SWOT Analysis601
    M&A and Licensing Deals611
  STADA s Group621
    Company Overview621
    SWOT Analysis622
    M&A, and Licensing Deals641
  Mylan651
    Company Overview651
    SWOT Analysis652
    M&A, and licensing Deals671
  DSM Pharmaceutical681
    Company Overview681
    SWOT Analysis691
    M&A, and Licensing Deals701
  Teva Pharmaceutical Industries711
    Company Overview711
    SWOT Analysis711
    M&A and Licensing Deals721
Manufacturing of Solid Dosage Forms: Emerging Companies735
  Catalent Pharma Solutions, Inc731
    Company Overview731
    Key Products and Services731
    Recent Updates Relating to Licensing Deals and Strategic Consolidations731
      Endotis Pharma, a biopharmaceutical company, entered into a co-development agreement with Catalent Pharma Solutions731
      BAVARIA Industriekapital AG, a German Industrial Holding Company, Acquired the Oral Dose Manufacturing Business (Osny) from Catalent Pharma Solutions731
      Oso Biopharmaceuticals Manufacturing, LLC, a Contract Manufacturing Company, Acquired Assets from Catalent Pharma Solutions731
  Merrion Pharmaceuticals Plc741
    Company Overview741
    Service Portfolio and Offerings741
    Recent Updates Related to Licensing Deals and Strategic Consolidations741
      Merrion Pharmaceuticals Wins US Patent for Orazol.741
      Merrion Pharmaceuticals Receives New US Patent741
  Emisphere Technologies, Inc.751
    Company Overview751
    Service Portfolio and Offerings751
    Recent Updates Related to Licensing Deals, Strategic Consolidations751
      Emisphere Technologies Completes Private Placement of $3.5m751
      Emisphere Reports Net Loss of $13.7m for Q2 2010751
      Emisphere Reports Interim Data from Oral Eligen B12 Study751
  Chiasma Ltd.751
    Company Overview751
    Service Portfolio and Offerings761
    Recent Updates Related to Licensing Deals and Strategic Consolidations761
      Debt Financing worth $4m761
      Licensing Agreement with Novartis AG.761
      Secured $9m in Series B Preferred Stock Financing761
      Secured $44m in Series C Financing761
  Oramed Pharmaceuticals771
    Company Overview771
    Service Portfolio and Offerings771
    Recent Updates Related to Licensing Deals and Strategic Consolidations771
      Oramed Pharmaceuticals Forms Joint Venture with Laser Detect Systems771
      Oramed Completes Pivotal Phase IIb Clinical Trial of ORMD-0801 for Type 2 Diabetes.771
Manufacturing of Solid Dosage Forms: Appendix784
  Market Definitions781
  Abbreviations781
  Research Methodology792
    Coverage791
    Secondary Research791
    Primary Research801
    Expert Panel Validation801
  Contact Us801
  Disclaimer801
  Sources811

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Manufacturing of Solid Dosage Forms - 2011" Feb 10, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Manufacturing-of-Solid-Dosage-Forms-2011-2115-164>
  
APA:
GBI Research Reports. (2011). Manufacturing of Solid Dosage Forms - 2011 Feb 10, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Manufacturing-of-Solid-Dosage-Forms-2011-2115-164>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.